Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Cardiovascular·MeSH: Heart Failure
Prevalence
1800.0 / 100K
Incidence
300.0 / 100K/yr
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| ck-4021586 (150 mg | CYTOKINETICS INC (CYTK) |
Frequently asked questions
How many drugs are in development for Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)?
BioSniper tracks 1 drug in development for Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) across 1 company.
How many clinical trials target Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)?
There are 1 clinical trial targeting Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) tracked by BioSniper.
What is the prevalence of Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)?
The estimated prevalence of Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF) is approximately 1800.0 per 100,000 population.
Deep-dive into Symptomatic Heart Failure With Preserved Ejection Fraction (HFpEF)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis